Celldex Therapeutics (NASDAQ: CLDX) revenue
Celldex Therapeutics reported revenue of $1.5m for fiscal 2025, 78.0% less than in fiscal 2024 ($7.0m). Since fiscal 2016 its revenue has fallen by 77.2%, an average decline of 15.2% a year.
Celldex Therapeutics's best year of the last 10 was fiscal 2017. The biggest drop was in fiscal 2025, −78.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $1.5m | −78.0% | −$287.4m | −18,599.8% |
| 2024 | $7.0m | +2.0% | −$195.1m | −2,778.9% |
| 2023 | $6.9m | +192.0% | −$154.5m | −2,245.3% |
| 2022 | $2.4m | −49.3% | −$115.2m | −4,889.0% |
| 2021 | $4.7m | −37.3% | −$71.2m | −1,531.8% |
| 2020 | $7.4m | +107.6% | −$63.4m | −854.1% |
| 2019 | $3.6m | −62.5% | −$55.0m | −1,540.2% |
| 2018 | $9.5m | −25.2% | −$156.4m | −1,640.1% |
| 2017 | $12.7m | +87.8% | −$121.5m | −953.7% |
| 2016 | $6.8m | — | −$132.9m | −1,958.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Celldex Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Celldex Therapeutics ranks 394th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Celldex Therapeutics, −78.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 392nd | Allogene Therapeutics | $2.6m | 2,500.0% |
| 393rd | Oramed Pharmaceuticals | $2.0m | — |
| 394th | Celldex Therapeutics | $1.5m | −78.0% |
| 395th | Inhibrx Biosciences | $1.3m | 550.0% |
| 396th | Shattuck Labs | $1.0m | −82.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Celldex Therapeutics
- How much revenue did Celldex Therapeutics make in fiscal 2025?
- Celldex Therapeutics reported revenue of $1.5m for fiscal 2025, compared with $7.0m in fiscal 2024.
- How much has the revenue of Celldex Therapeutics fallen?
- Between fiscal 2016 and fiscal 2025 it went from $6.8m to $1.5m: 77.2% less, an average decline of 15.2% a year.
- What was the best year for revenue at Celldex Therapeutics?
- Of its last 10 fiscal years, fiscal 2017, with $12.7m.
- Where does Celldex Therapeutics rank in its sector by revenue?
- It ranks 394th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Celldex Therapeutics come from?
- From the annual report (Form 10-K) that Celldex Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Celldex Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Celldex Therapeutics: the Celldex Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.